Market Tracker

06/29 5:16pm ET

Exelixis Inc (NASDAQ:EXEL)

7.80
Delayed Data
As of Jun 29
 +0.02 / +0.26%
Today’s Change
3.31
Today|||52-Week Range
7.90
+38.30%
Year-to-Date
Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis...
Jun 29 / Zacks.com - Paid Partner Content
5 Reasons to Hate Biotech Stocks
Jun 23 / MotleyFool.com - Paid Partner Content
Explosive Stocks Under $10
Jun 28 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close7.78
Today’s open7.90
Day’s range7.63 - 7.90
Volume6,261,065
Average volume (3 months)5,278,732
Market cap$1.8B
Dividend yield--
Data as of 4:00pm ET, 06/29/2016

Growth & Valuation

Earnings growth (last year)+41.30%
Earnings growth (this year)-20.37%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+48.03%
P/E ratioNM
Price/Sales31.75
Price/Book--

Competitors

 Today’s
change
Today’s
% change
NKTRNektar Therapeutics+0.21+1.53%
INCRINC Research Holding...+0.31+0.82%
DBVTDBV Technologies SA+1.29+4.15%
LXRXLexicon Pharmaceutic...+0.65+4.79%
Data as of 4:00pm ET, 06/29/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)-$0.28
Annual revenue (last year)$37.2M
Annual profit (last year)-$169.7M
Net profit margin-456.63%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Michael M. Morrissey
Chief Financial Officer &
Executive Vice President
Christopher J. Senner
Corporate headquarters
South San Francisco, California

Forecasts